Login / Signup

Do we need to adjust for interim analyses in a Bayesian adaptive trial design?

Elizabeth G RyanKristian BrockSimon GatesDaniel Slade
Published in: BMC medical research methodology (2020)
Currently, regulators require demonstration of control of type I error for both frequentist and Bayesian adaptive designs, particularly for late-phase trials. To demonstrate control of type I error in Bayesian adaptive designs, adjustments to the stopping boundaries are usually required for designs that allow for early stopping for efficacy as the number of analyses increase. If the designs only allow for early stopping for futility then adjustments to the stopping boundaries are not needed to control type I error. If one instead uses a strict Bayesian approach, which is currently more accepted in the design and analysis of exploratory trials, then type I errors could be ignored and the designs could instead focus on the posterior probabilities of treatment effects of clinically-relevant values.
Keyphrases
  • finite element analysis
  • clinical trial
  • randomized controlled trial
  • transcription factor
  • emergency department
  • phase iii
  • combination therapy
  • smoking cessation